Erythropoietin biosimilar - SciGenAlternative Names: SciPogen
Latest Information Update: 11 May 2015
At a glance
- Originator Intas Biopharmaceuticals
- Developer SciGen
- Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoietin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anaemia